SCIENCE IN THE NEWS DAILY
Promising Alzheimer's Drug Approved for Late-Stage Trials
from USA Today
An experimental drug for Alzheimer's disease patients showed promise in Phase II clinical trials and is moving into final-stage trials, Wyeth and Elan, the makers of bapineuzumab, announced Tuesday.
Bapineuzumab is designed to fight beta amyloid, a toxic protein that clumps together in the brains of Alzheimer's patients.
In the early studies, conducted around the USA, 240 people with early- to moderate-stage Alzheimer's disease were either assigned bapineuzumab or a placebo. Researchers reported that non-carriers of a gene considered to be a risk factor for Alzheimer's disease, called ApoE4, showed "clinically meaningful benefits" in a battery of tests used to track the progression of Alzheimer's disease.
Read more ...
Connect With Us:
PODCASTS: Expanding With the Cosmos
Using the Atacama Cosmology Telescope (ATC), a 6.5-meter microwave collector in Chile, cosmologists are piecing together the early history of the known universe. In an exclusive American Scientist interview, Arthur Kosowsky—a member of the ATC team and a professor in the Department of Physics and Astronomy at the University of Pittsburgh—discusses how he is using ATC to reach back in time billions of years to search for gravitational waves that could verify inflation and reveal unprecedented details about how the cosmos was born.
To view all multimedia content, click "Latest Multimedia."
Receive notification when new content is posted from the entire website, or choose from the customized feeds available.